Vaxcyte Completes Enrollment in Phase 3 VAX-31 Clinical Trials
Vaxcyte (NASDAQ:PCVX) has completed enrollment for its three Phase 3 clinical trials evaluating the pneumococcal vaccine candidate, VAX-31. Topline results from these studies are expected later this year and in early 2027.
Tickers: $PCVX
Topics: pneumococcal disease prevention vaccine development VAX-31